GRHL2 is a Candidate Prognostic and Immunotherapy Biomarker in Breast Cancer

Xiaoyu Bai,Yue Li,Yanlei Li,Fan Li,Na Che,Chunsheng Ni,Nan Zhao,Xiulan Zhao,Tieju Liu

DOI: https://doi.org/10.21203/rs.3.rs-999774/v1

2021-01-01

Abstract:Abstract Background:Breast cancer (BC) is the most frequent malignancy in women worldwide and the leading cause of female cancer‐associated death in the world. Thus, we need to identify new biomarkers to predict the prognosis of BC. In mammals, the Grainyhead-like (GRHL) family of transcription factors has three members, called Grainyhead-like 1 (GRHL1), Grainyhead-like 2 (GRHL2) and Grainyhead-like 3 (GRHL3). GRHL2 contributes to epithelial morphogenesis and differentiation.Materials & Methods: In this study, we explored the expresstion of GRHL2 across multiple databases, including Oncomine, the Human Protein Atlas (HPA), UALCAN, and the Cancer Cell Line Encyclopedia (CCLE). PrognoScan, GEPIA and Kaplan-Meier plotter were utilized to analyze the prognostic value of GRHL2 in certain cancers. Based on TCGA data, a receiver operating characteristic (ROC) curve was used to evaluate the diagnostic performance of GRHL2 expression. Using the GEPIA and TIMER databases, we investigated the correlations between GRHL2 expression and immune cell infiltration in breast cancer. In addition, the gene set enrichment analysis was performed to unveil the potential molecular mechanism of GRHL2 promoting breast cancer aggressiveness by using LinkedOmics and METASCAPE. Results: We demonstrated that tumor tissue had the higher expression level of GRHL2, compared with that in normal tissue. High expression of GRHL2 was associated with worse prognosis of breast cancer patients. ROC analysis indicated that GRHL2 had significant diagnostic value. Importantly, there were significant positive correlations between GRHL2 expression and immune infiltrates, including CD8+ T cells and macrophages in breast cancer. GRHL2 expression is regulated by methylation. Furthermore, KEGG and GO analysis showed GRHL2 related signaling pathways in breast cancer are related to tumor cells proliferation, invasion and angiogenesis. Conclusion:In summary, we demonstrate that GRHL2 can be used as a prognostic and immunotherapy biomarker for breast cancer.